Pharma Mar Says Jazz Pharmaceuticals To Seek FDA Withdrawal Of Zepzelca Second-line Use
JAZZ•Jazz to submit FDA labeling supplement
Aug. 4 (Reuters) - Pharma Mar SA PHMR.MC:
- Jazz Pharmaceuticals to submit FDA labeling supplement in Q3 to withdraw Zepzelca second-line indication
- Zepzelca first-line maintenance indication remains unchanged
Source text
Further company coverage: PHMR.MC
